Media ReleasesNyrada

View All Nyrada News

57% Reduction in Total Cholesterol from Nyradas NYX-PCSK9i In Vivo Study

Nyrada Inc (ASX: NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol). 

For more information, please refer to the attached PDF.
Download this document